Integrated Pharmacodynamic Analysis Identifies Two Metabolic Adaption Pathways to Metformin in Breast Cancer
Simon R Lord, Wei-Chen Cheng, Dan Liu, Edoardo Gaude, Syed Haider, Tom Metcalf, Neel Patel, Eugene J Teoh, Fergus Gleeson, Kevin Bradley, Simon Wigfield, Christos Zois, Daniel R McGowan, Mei-Lin Ah-See, Alastair M Thompson, Anand Sharma, Luc Bidaut, Michael Pollak, Pankaj G Roy, Fredrik Karpe, Tim James, Ruth English, Rosie F Adams, Leticia Campo, Lisa Ayers, Cameron Snell, Ioannis Roxanis, Christian Frezza, John D Fenwick, Francesca M Buffa, Adrian L Harris, Simon R Lord, Wei-Chen Cheng, Dan Liu, Edoardo Gaude, Syed Haider, Tom Metcalf, Neel Patel, Eugene J Teoh, Fergus Gleeson, Kevin Bradley, Simon Wigfield, Christos Zois, Daniel R McGowan, Mei-Lin Ah-See, Alastair M Thompson, Anand Sharma, Luc Bidaut, Michael Pollak, Pankaj G Roy, Fredrik Karpe, Tim James, Ruth English, Rosie F Adams, Leticia Campo, Lisa Ayers, Cameron Snell, Ioannis Roxanis, Christian Frezza, John D Fenwick, Francesca M Buffa, Adrian L Harris
Abstract
Late-phase clinical trials investigating metformin as a cancer therapy are underway. However, there remains controversy as to the mode of action of metformin in tumors at clinical doses. We conducted a clinical study integrating measurement of markers of systemic metabolism, dynamic FDG-PET-CT, transcriptomics, and metabolomics at paired time points to profile the bioactivity of metformin in primary breast cancer. We show metformin reduces the levels of mitochondrial metabolites, activates multiple mitochondrial metabolic pathways, and increases 18-FDG flux in tumors. Two tumor groups are identified with distinct metabolic responses, an OXPHOS transcriptional response (OTR) group for which there is an increase in OXPHOS gene transcription and an FDG response group with increased 18-FDG uptake. Increase in proliferation, as measured by a validated proliferation signature, suggested that patients in the OTR group were resistant to metformin treatment. We conclude that mitochondrial response to metformin in primary breast cancer may define anti-tumor effect.
Trial registration: ClinicalTrials.gov NCT01266486.
Keywords: breast neoplasms; cancer metabolism; clinical study; gene expression profiling; metabolomics; metformin; mitochondria; positron emission tomography.
Crown Copyright © 2018. Published by Elsevier Inc. All rights reserved.
Figures
References
- Anders S., Huber W. Differential expression analysis for sequence count data. Genome Biol. 2010;11:R106.
- Ben Sahra I., Laurent K., Giuliano S., Larbret F., Ponzio G., Gounon P., Le Marchand-Brustel Y., Giorgetti-Peraldi S., Cormont M., Bertolotto C. Targeting cancer cell metabolism: the combination of metformin and 2-deoxyglucose induces p53-dependent apoptosis in prostate cancer cells. Cancer Res. 2010;70:2465–2475.
- Bertoldo A., Peltoniemi P., Oikonen V., Knuuti J., Nuutila P., Cobelli C. Kinetic modeling of [(18)F]FDG in skeletal muscle by PET: a four-compartment five-rate-constant model. Am. J. Physiol. Endocrinol. Metab. 2001;281:E524–E536.
- Birsoy K., Possemato R., Lorbeer F.K., Bayraktar E.C., Thiru P., Yucel B., Wang T., Chen W.W., Clish C.B., Sabatini D.M. Metabolic determinants of cancer cell sensitivity to glucose limitation and biguanides. Nature. 2014;508:108–112.
- Birsoy K., Wang T., Chen W.W., Freinkman E., Abu-Remaileh M., Sabatini D.M. An essential role of the mitochondrial electron transport chain in cell proliferation is to enable aspartate synthesis. Cell. 2015;162:540–551.
- Bos R., van Der Hoeven J.J., van Der Wall E., van Der Groep P., van Diest P.J., Comans E.F., Joshi U., Semenza G.L., Hoekstra O.S., Lammertsma A.A. Biologic correlates of (18)fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. J. Clin. Oncol. 2002;20:379–387.
- Cardaci S., Zheng L., MacKay G., van den Broek N.J., MacKenzie E.D., Nixon C., Stevenson D., Tumanov S., Bulusu V., Kamphorst J.J. Pyruvate carboxylation enables growth of SDH-deficient cells by supporting aspartate biosynthesis. Nat. Cell Biol. 2015;17:1317–1326.
- Chae Y.C., Vaira V., Caino M.C., Tang H.Y., Seo J.H., Kossenkov A.V., Ottobrini L., Martelli C., Lucignani G., Bertolini I. Mitochondrial Akt regulation of hypoxic tumor reprogramming. Cancer Cell. 2016;30:257–272.
- Chandel N.S., Avizonis D., Reczek C.R., Weinberg S.E., Menz S., Neuhaus R., Christian S., Haegebarth A., Algire C., Pollak M. Are metformin doses used in murine cancer models clinically relevant? Cell Metab. 2016;23:569–570.
- Chen W.W., Freinkman E., Wang T., Birsoy K., Sabatini D.M. Absolute quantification of matrix metabolites reveals the dynamics of mitochondrial metabolism. Cell. 2016;166:1324–1337.e11.
- Desmedt C., Haibe-Kains B., Wirapati P., Buyse M., Larsimont D., Bontempi G., Delorenzi M., Piccart M., Sotiriou C. Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin. Cancer Res. 2008;14:5158–5165.
- Dowling R.J., Lam S., Bassi C., Mouaaz S., Aman A., Kiyota T., Al-Awar R., Goodwin P.J., Stambolic V. Metformin pharmacokinetics in mouse tumors: implications for human therapy. Cell Metab. 2016;23:567–568.
- Dowling R.J., Niraula S., Chang M.C., Done S.J., Ennis M., McCready D.R., Leong W.L., Escallon J.M., Reedijk M., Goodwin P.J. Changes in insulin receptor signaling underlie neoadjuvant metformin administration in breast cancer: a prospective window of opportunity neoadjuvant study. Breast Cancer Res. 2015;17:32.
- Dowling R.J., Niraula S., Stambolic V., Goodwin P.J. Metformin in cancer: translational challenges. J. Mol. Endocrinol. 2012;48:R31–R43.
- Dunnwald L.K., Doot R.K., Specht J.M., Gralow J.R., Ellis G.K., Livingston R.B., Linden H.M., Gadi V.K., Kurland B.F., Schubert E.K. PET tumor metabolism in locally advanced breast cancer patients undergoing neoadjuvant chemotherapy: value of static versus kinetic measures of fluorodeoxyglucose uptake. Clin. Cancer Res. 2011;17:2400–2409.
- Fendt S.M., Bell E.L., Keibler M.A., Davidson S.M., Wirth G.J., Fiske B., Mayers J.R., Schwab M., Bellinger G., Csibi A. Metformin decreases glucose oxidation and increases the dependency of prostate cancer cells on reductive glutamine metabolism. Cancer Res. 2013;73:4429–4438.
- Gaude E., Schmidt C., Gammage P.A., Dugourd A., Blacker T., Chew S.P., Saez-Rodriguez J., O'Neill J.S., Szabadkai G., Minczuk M. NADH shuttling couples cytosolic reductive carboxylation of glutamine with glycolysis in cells with mitochondrial dysfunction. Mol. Cell. 2018;69:581–593.e7.
- Gillessen S., Gilson C., James N., Adler A., Sydes M.R., Clarke N., STAMPEDE Trial Management Group Repurposing metformin as therapy for prostate cancer within the STAMPEDE trial platform. Eur. Urol. 2016;70:906–908.
- Goodwin P.J., Parulekar W.R., Gelmon K.A., Shepherd L.E., Ligibel J.A., Hershman D.L., Rastogi P., Mayer I.A., Hobday T.J., Lemieux J. Effect of metformin vs placebo on and metabolic factors in NCIC CTG MA.32. J. Natl. Cancer Inst. 2015;107
- Hadad S., Iwamoto T., Jordan L., Purdie C., Bray S., Baker L., Jellema G., Deharo S., Hardie D.G., Pusztai L. Evidence for biological effects of metformin in operable breast cancer: a pre-operative, window-of-opportunity, randomized trial. Breast Cancer Res. Treat. 2011;128:783–794.
- Haugrud A.B., Zhuang Y., Coppock J.D., Miskimins W.K. Dichloroacetate enhances apoptotic cell death via oxidative damage and attenuates lactate production in metformin-treated breast cancer cells. Breast Cancer Res. Treat. 2014;147:539–550.
- Hume R. Prediction of lean body mass from height and weight. J. Clin. Pathol. 1966;19:389–391.
- Joshua A.M., Zannella V.E., Downes M.R., Bowes B., Hersey K., Koritzinsky M., Schwab M., Hofmann U., Evans A., van der Kwast T. A pilot 'window of opportunity' neoadjuvant study of metformin in localised prostate cancer. Prostate Cancer Prostatic Dis. 2014;17:252–258.
- Laskov I., Drudi L., Beauchamp M.C., Yasmeen A., Ferenczy A., Pollak M., Gotlieb W.H. Anti-diabetic doses of metformin decrease proliferation markers in tumors of patients with endometrial cancer. Gynecol. Oncol. 2014;134:607–614.
- Liu D., Chalkidou A., Landau D.B., Marsden P.K., Fenwick J.D. 18F-FLT uptake kinetics in head and neck squamous cell carcinoma: a PET imaging study. Med. Phys. 2014;41:041911.
- Liu X., Romero I.L., Litchfield L.M., Lengyel E., Locasale J.W. Metformin targets central carbon metabolism and reveals mitochondrial requirements in human cancers. Cell Metab. 2016;24:728–739.
- McCarthy D.J., Chen Y., Smyth G.K. Differential expression analysis of multifactor RNA-Seq experiments with respect to biological variation. Nucleic Acids Res. 2012;40:4288–4297.
- Mehta S., Hughes N.P., Li S., Jubb A., Adams R., Lord S., Koumakis L., van Stiphout R., Padhani A., Makris A. Radiogenomics monitoring in breast cancer identifies metabolism and immune checkpoints as early actionable mechanisms of resistance to anti-angiogenic treatment. EBioMedicine. 2016;10:109–116.
- Mitsuhashi A., Kiyokawa T., Sato Y., Shozu M. Effects of metformin on endometrial cancer cell growth in vivo: a preoperative prospective trial. Cancer. 2014;120:2986–2995.
- Mullen A.R., Wheaton W.W., Jin E.S., Chen P.H., Sullivan L.B., Cheng T., Yang Y., Linehan W.M., Chandel N.S., DeBerardinis R.J. Reductive carboxylation supports growth in tumour cells with defective mitochondria. Nature. 2011;481:385–388.
- Niraula S., Dowling R.J., Ennis M., Chang M.C., Done S.J., Hood N., Escallon J., Leong W.L., McCready D.R., Reedijk M. Metformin in early breast cancer: a prospective window of opportunity neoadjuvant study. Breast Cancer Res. Treat. 2012;135:821–830.
- Robey R.B., Hay N. Is Akt the “Warburg kinase”?-Akt-energy metabolism interactions and oncogenesis. Semin. Cancer Biol. 2009;19:25–31.
- Robinson M.D., McCarthy D.J., Smyth G.K. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2010;26:139–140.
- Schooneman M.G., Vaz F.M., Houten S.M., Soeters M.R. Acylcarnitines: reflecting or inflicting insulin resistance? Diabetes. 2013;62:1–8.
- Schuler K.M., Rambally B.S., DiFurio M.J., Sampey B.P., Gehrig P.A., Makowski L., Bae-Jump V.L. Antiproliferative and metabolic effects of metformin in a preoperative window clinical trial for endometrial cancer. Cancer Med. 2015;4:161–173.
- Sonnenblick A., Agbor-Tarh D., Bradbury I., Di Cosimo S., Azim H.A., Jr., Fumagalli D., Sarp S., Wolff A.C., Andersson M., Kroep J. Impact of diabetes, insulin, and metformin use on the outcome of patients with human epidermal growth factor receptor 2-positive primary breast cancer: analysis from the ALTTO phase III randomized trial. J. Clin. Oncol. 2017;35:1421–1429.
- Sullivan L.B., Gui D.Y., Hosios A.M., Bush L.N., Freinkman E., Vander Heiden M.G. Supporting aspartate biosynthesis is an essential function of respiration in proliferating cells. Cell. 2015;162:552–563.
- Wheaton W.W., Weinberg S.E., Hamanaka R.B., Soberanes S., Sullivan L.B., Anso E., Glasauer A., Dufour E., Mutlu G.M., Budigner G.S. Metformin inhibits mitochondrial complex I of cancer cells to reduce tumorigenesis. Elife. 2014;3:e02242.
- Zhang L., Han J., Jackson A.L., Clark L.N., Kilgore J., Guo H., Livingston N., Batchelor K., Yin Y., Gilliam T.P. NT1014, a novel biguanide, inhibits ovarian cancer growth in vitro and in vivo. J. Hematol. Oncol. 2016;9:91.
Source: PubMed